SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : qtrn(quintiles trans)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: ToTradeWell who wrote (40)9/23/1999 8:20:00 PM
From: RWReeves  Read Replies (1) of 105
 
CRO's are not going to go away. FDA wants more and better data, corporate clinical groups are expensive to feed and maintain (maybe the most expensive groups) and there are a lot of start-up costs for trials and sites that CRO's can leverage. A lot of those pipelines we talk about are going to run right through CROs.

QTRN continues to look like the leader in this area (although I also like Covance's contract manufacturing foray). Seems like just a matter of time before the best get priced to reflect the value.

RWR
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News